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The medium chain triglyceride (MCT) ketogenic diet is used extensively for treating refractory childhood
epilepsy. This diet increases the plasma levels of medium straight chain fatty acids. A role for these and
related fatty acids in seizure control has not been established. We compared the potency of an estab-
lished epilepsy treatment, Valproate (VPA), with a range of MCT diet-associated fatty acids (and related
branched compounds), using in vitro seizure and in vivo epilepsy models, and assessed side effect
potential in vitro for one aspect of teratogenicity, for liver toxicology and in vivo for sedation, and for
a neuroprotective effect. We identify speciﬁc medium chain fatty acids (both prescribed in the MCT diet,
and related compounds branched on the fourth carbon) that provide signiﬁcantly enhanced in vitro
seizure control compared to VPA. The activity of these compounds on seizure control is independent of
histone deacetylase inhibitory activity (associated with the teratogenicity of VPA), and does not correlate
with liver cell toxicity. In vivo, these compounds were more potent in epilepsy control (perforant
pathway stimulation induced status epilepticus), showed less sedation and enhanced neuroprotection
compared to VPA. Our data therefore implicates medium chain fatty acids in the mechanism of the MCT
ketogenic diet, and highlights a related new family of compounds that are more potent than VPA in
seizure control with a reduced potential for side effects.
This article is part of the Special Issue entitled ‘New Targets and Approaches to the Treatment of
Epilepsy’.
 2012 Elsevier Ltd. Open access under CC BY license. 1. Introduction
The medium chain triglyceride (MCT) ketogenic diet has
provided one of the most effective therapeutic approaches for
children with drug resistant epilepsy (Kossoff et al., 2009; Liu,
2008; Neal et al., 2009; Rho and Stafstrom, 2012; Sills et al.,
1986b; Vining et al., 1998). However, its use has been limited by
poor tolerability, especially in adults, raising the need for the
development of novel therapies based upon this diet. The MCT diet
causes a rise in ketone body formation, but this correlates poorly
with seizure control (Likhodii et al., 2000; Thavendiranathan et al.,
2000). It also causes accumulation of medium chain fatty acids in
blood plasma (in particular octanoic and decanoic acids, Fig. 1A)
(Haidukewych et al., 1982; Newport et al., 1979; Sills et al., 1986a),
although the role of these fatty acids, if any, in seizure control
remains unclear.fax: þ44 1784 414224.
r), robin.williams@rhul.ac.uk
 license. The short chain fatty acid valproic acid (VPA, 2-propylpentanoic
acid), is a commonly used broad-spectrum antiepileptic drug, but is
sub-optimal due to numerous side effects: The two most signiﬁcant
of these are teratogenicity (Jentink et al., 2010; Koren et al., 2006),
which has been correlated with inhibition of histone deacetylase
activity (Gottlicher et al., 2001; Gurvich et al., 2004; Phiel et al., 2001)
although other mechanism may also function here; and hepatotox-
icity (Lagace et al., 2005; Stephens and Levy, 1992), potentially
due to effects on b-oxidation (Elphick et al., 2011; Silva et al., 2008).
Additionally, fattyacidswith structures related toVPAhave also been
associated with signiﬁcant sedative properties, often preventing
translation into clinical trials (Bojic et al., 1996; Keane et al., 1983;
Palaty and Abbott, 1995). These effects have inﬂuenced the search
for novel fatty acid structures with increased potency against
seizures and with a better side-effect proﬁle than VPA.
In the search for new seizure control treatments, a recent study
suggested that the action of VPA involves modiﬁcation of phos-
phoinositol turnover in the social amoeba Dictyostelium discoideum
(Chang et al., 2011). Based on this mechanism, a group of medium
chain fatty acids including both MCT-diet associated compounds
Fig. 1. Structurally-speciﬁc medium chain fatty acids strongly reduce frequency of in vitro epileptiform activity. (A) A range of medium chain fatty acids were analysed in this study:
Straight medium chain fatty acids octanoic (OA), nonanoic (NA) and decanoic (DA) acids contain 8, 9 and 10 carbon backbones respectively. Related structures analysed are derivates
of octanoic acid branched at the second carbon (2-propyloctanoic acid (2-PO) and 2-butyloctanoic acid (2-BO)) and the fourth carbon (4-methyloctanoic acid (4-MO) and 4-
ethyloctanoic acid (4-EO)); and two related structures, a heptanoic acid derivative (7 carbon backbone) branched on the second carbon (2-methylheptanoic acid (2-MH)), and
an octanoic acid derivative branched on both the third and the seventh carbon (3,7-dimethyloctanoic acid (3,7-DO)). The frequency of epileptiform activity is plotted against time
following (B) control (DMSO) and 3,7-DO (n ¼ 3) gave no effect on epileptiform activity, whereas VPA and 2-MH (n ¼ 3) treatment showed a weak effect. (C) The straight chain fatty
acid OA showed no effect, whereas a strong effect was shown for NA and DA. (D) Octanoic acid derivatives branched on the second carbon, 2-PO, 2-BO; and (E) on the fourth carbon
4-MO, 4-EO are also highly active. (F) Comparison of the mean frequency of PTZ-induced burst discharges, averaged from 20 to 40 min post compound addition (data shown as
means  SEM). * and ** indicate a signiﬁcant difference at p < 0.05 or p < 0.01 compared to control respectively; þ and þþ indicate similar levels of signiﬁcance compared to VPA.
Data is provided for all compounds tested at 1 mM from at least ﬁve repeats unless indicated. Illustrative trace recordings plotted against time for all compounds are provided in
Supplementary Fig. 1.
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potential new therapeutics for epilepsy. A better understanding of
these compounds could therefore aid in the production of more
effective treatments for epilepsy.
In this study, we investigated the potency of a range of medium
straight and branched chain fatty acids in seizure control using an
in vitro model system, enabling precise drug dosing, avoidance of
confounders such as metabolism/blood brain barrier and rapid
throughput, in comparison to VPA. We used an in vitro model in
which VPA at high doses (2mM) shows only partial efﬁcacy (Armand
et al., 1998) in order to identify compounds that are potentially
superior to VPA. We then assessed the resulting active compounds
forhistone deacetylase inhibition and liver toxicology to identify two
promising medium chain fatty acids for further investigation. These
two compounds showed dose dependent seizure control in the in
vitro (PTZ) model, and more potent seizure control than VPA in vivo,
using a drug-resistant status epilepticus (perforant pathway stimu-
lation model) (Holtkamp et al., 2001). Furthermore, we show that
one of these compounds causes less sedation and has a greater
neuroprotective (potentially diseasemodifying) effect than VPA. Our
data thus indicate a series of fattyacidwhich show increasedpotency
in seizure control and potentially reduced side effects compared to
the currently available antiepileptic drug, VPA.
2. Materials and methods
2.1. Animals
Male Sprague-Dawley rats (SD) were kept under controlled environmental
conditions (24e25 C; 50e60% humidity; 12 h light/dark cycle) with free access to
food and water. All the experiments were performed in accordance with the
guidelines of the Animals (Scientiﬁc Procedures) Act 1986. All efforts were made to
minimise animal suffering and to reduce the number of animals used.
2.2. In vitro electrophysiology
The preparation of entorhinal cortexehippocampus slices and electrophysiolog-
ical recording in CA1 were described previously (Chang et al., 2010). In brief, SD rats
(50e150 g) were decapitated after killing by intraperitoneal injection with an over-
dose ofpentobarbitone (500mg/kg). Thebrainwas removedandplaced inoxygenated
ice-cold sucrose solution (in mM: NaCl 87, KCl 2.5, MgCl2 7, CaCl2 0.5, NaH2PO4 1.25,
NaHCO3 26.2 sucrose 75 and glucose 3). Slices (350 mm) were prepared with a Leica
vibratome (Leica VT1200S) and were then stored in an interface chamber containing
artiﬁcial cerebrospinal ﬂuid solution (aCSF, in mM: NaCl 119, KCl 2.5, MgSO41.3, CaCl2
2.5,NaH2PO41,NaHCO3 26.2 andglucose16.6) forover 1h.During theexperiment, the
slices were transferred from the interface chamber into a submerged recording
chamber and continuously perfused with prewarmed (36 C) oxygenated aCSF (95%
O2, 5%CO2). Fieldpotentialswere recordedwith a glassmicroelectrode (1e2MU)ﬁlled
with aCSF solution placed in stratum radiatum of CA1 and were ﬁltered at 1 kHz and
digitized at 2 kHz (usingannpi EXT-02Fextracellular ampliﬁer recordedwithWinEDR
software). To induce epileptiform activity, pentylenetetrazol (PTZ) (2mM)was added
to the perfusate and [Kþ] was increased (to 6 mM). Once the frequency of the
epileptiform discharges was stable over a period of 10 min, compounds were applied
to the perfusate for the following 40min, andwashed out for a remaining 20min. The
anticonvulsant effects were evaluated by measuring the variation of frequency of the
discharges every minute. The discharge frequency was then averaged every 5 min
during the experiment and normalized to baseline. The testing compounds including
VPA (VPA, 0.1, 0.5 and 1mM) (Sigma), 4-methyloctanoic acid (0.1, 0.5 and 1mM) (Alfa
Aesar) and nonanoic acid (0.1, 0.5 and 1 mM) (Alfa Aesar), octanoic acid (1 mM) (Alfa
Aesar), decanoic acid (1 mM) (Alfa Aesar), 4-ethyloctanoic acid (1 mM), 2-
propyloctanoic acid (1 mM) (ChemSampCo), 2-butyloctanoic acid (1 mM) (Sigma),
2-methylheptanoic acid (1 mM) (Alfa Aesar) and 3,7 dimethyloctanoic acid (1 mM)
(Chemos, Gmbh), and valnoctamide (0.1 mM) (kindly provided by Meir Bialer, The
Hebrew University of Jerusalem). Compounds were prepared as 1000 times stocks in
dimethyl sulfoxide (DMSO), except VPA was dissolved in distilled water. Stocks were
dissolved in aCSF to achieve their ﬁnal concentrations during experiments.
2.3. HDAC activity assay
Histonedeacetylase (HDAC) activitywas analysed byusing an in vitro commercial
assay, the drug discovery HDAC activity kit (Biomol, Plymouth Meeting, PA). The
assays were conducted at room temperature according to the manufacturer’s
protocol, using Trichostatin A (HDAC Inhibitor; 1 mM) as a positive control. Data was
normalized to controls (without VPA or testing compounds) for each experiment.2.4. Hepatic toxicity assay
The Hepatic toxicity assay employed Huh7 cells, kindly provided by Dr Steve Hood
(GlaxoSmithKline), cultured in Dulbecco’s modiﬁed eagle medium (DMEM) with L-
glutamine and phenol red, containing 10% foetal bovine serum,1% non-essential amino
acids, 100 U/ml penicillin and 100 mg/ml streptomycin. All cell culture reagents were
purchased fromInvitrogen (Paisley,UK). Cellswere seededat 1104 cells perwell in 96-
well plates overnight andgrown to approximately 80% cell conﬂuence prior to exposure
to 0.01e5mM testing compound (or vehicle control maintained below 0.5% (v/v) for all
conditions). Following exposure to testing compound for 24 h, 0.5 mg/ml 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was added and cells
incubated fora further2h to allowcolourdevelopment.Mediumwasthenaspiratedand
replaced with 100 mL DMSO per well, and absorbance read at 540 nm.
2.5. In vivo status epilepticus model
SD rats (300e400mg)were anesthetizedwith 1e2% isoﬂurane in O2 (at aﬂow rate
of 2 L/minutes). A recording electrode was stereotaxically implanted into the dentate
gyrus (coordinates: lateral 2.5mm frommidline, antero-posterior 4mm frombregma).
A bipolar stimulating electrode was implanted in the right hemisphere and advanced
into the angular bundle (coordinates, 4.4 mm lateral and 8.1 mm caudal from bregma)
to stimulate the perforant path. These stereotaxic coordinates relative to bregmawere
based on the atlas of Paxinos and Watson (1998). The depths of the electrodes were
adjusted tomaximize the slopeof thedentate granule cellﬁeldpotential. Following two
weeks recovery, the perforant path was electrically stimulated with 3e5 mA 50 msec
monopolar pulses at 20 Hz for 2 h to induce self-sustaining status epilepticus (SSSE),
and the ﬁeld potential was recorded from the dentate granule bandpass-ﬁltered (0.1e
50Hz), and thendigitized at 100Hzusing a CEDmicro 1401 and SPIKE 2 software (both
CED, Cambridge, United Kingdom). After 10 min of SSSE, testing compounds (VPA, 4-
methyloctanoic acid or nonanoic acid; 400 mg/kg) or vehicle control (DMSO) were
administered intraperitoneally (i.p.), and behavioural seizures and EEG monitored for
3 h. At this point diazepam (10 mg/kg, i.p.) was administered to all animals to stop the
SSSE. If necessary, this dose of diazepam was repeated until motor and EEG seizure
activity ceased in all animals. Behavioural seizures were monitored every 10 min and
classiﬁedusing the Racine scale. Stage 1, facial automatisms; Stage 2: headnodding and
more severe facial and mouth movements; Stage 3: forelimb clonus with a lordotic
posture; Stage 4: bilateral forelimb clonus continues alongwith rearing; Stage 5: falling
to one side ﬁrst and forelimb clonus.
The in vivo data were analysed by repeated ANOVA analysis with time of
measurement as thewithin-subject factor and the treatment as the between-subject
factor. Post-hoc analysis of treatments against control was performed using 2-sided
Dunnett t test and comparison between treatments was performed using Tukey HSD
test in SPSS (version 20).
For histology, animals were sacriﬁced 2 months post-SSSE, with an overdose of
pentobarbital sodium (500mg/kg i.p.) (Fort dodge Animal Health, Southampton, UK)
and the brains were immersed in 4% paraformaldehyde in 0.1 M phosphate-buffered
saline pH 7.4 (PBS) for over 24 h and then stored at 4 C prior to transfer to PBS with
30% sucrose as a post-ﬁxation solution. Brain sections (40 mm thick thickness) were
cut using a vibroslicer (Leica VT 1000S Microsystems, Wetzlar, Germany) and Nissl
staining was used to conﬁrm the position of electrodes and examine the degree of
neurodegeneration in the hilus using particle analysis in ImageJ software (this
calculates the proportion of the hilus inwhich cell nuclei are present) in comparable
sections from each animal (averaged data from four slices per treatment).
2.6. Sedation experiment
VPA, 4-methyloctanoic acid and nonanoic acid were administered (i.p.) at 200,
400 or 600 mg/kg to male SD rats. The degree of sedation was assessed by using
a well-established scale: 0, spontaneous movement; 1, intermittent spontaneous
movement; 2, no spontaneousmovement; 3, loss of auditory reﬂex; 4, loss of corneal
reﬂex; 5, loss of response to tail pinch (Fisher et al., 2004; Holtkamp et al., 2001; Lee
et al., 1998). The level of sedation was recorded at 10 min after i.p. injection, and
thereafter every 30 min for 3 h.
2.7. Statistical analysis
In all data provided, results are presented as mean  SEM. Statistical compari-
sons were performed by using the ManneWhitney test, and one way ANOVA fol-
lowed by Dunnett for post hoc analysis using SPSS.
3. Results
3.1. The effect of medium chain fatty acids on in vitro seizure
control activity
We have previously identiﬁed a range of related medium
straight and branched chain fatty acids with a similar mode of
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2011; Williams et al., 2006). We thus examined the ability of
these compounds to inhibit epileptiform activity in an in vitro PTZ
model (at 1 mM) in which VPA is only partially effective (Armand
et al., 1998), where epileptiform discharges consisted of a positive
ﬁeld potential on which multiple population spikes were super-
imposed. VPA caused a small but signiﬁcant decrease in the
frequency of epileptiform discharges (77.1 2.0% of baseline) (Fig. 1
and Supplementary Fig. S1). Octanoic acid had no effect on seizure
control (OA; 98.4  7.2%), whilst nonanoic and decanoic acid
exhibitedmarked effects (NA; 23.2 8.2% and DA; 2.21.4%) (Fig.1
and Supplementary Fig. S1). Introduction of a side chain to octanoic
acid increased suppression of PTZ-induced epileptiform discharges
when branched on the second carbon (2-propyloctanoic acid (2-
PO; 11.1  4.6%) and 2-butyloctanoic acid (2-BO; 9.2  7.1%)); or
the fourth carbon (4-methyloctanoic (4-MO; 50.0  3.8%) and 4-
ethyloctanoic (4-EO; 5.8  3.8%)). Epileptiform discharge inhibi-
tion was structurally speciﬁc, since 3,7-dimethyloctanoic acid (3,7-
DO; 96.7  2.6%) and 2-methylheptanoic acid (2-MH; 84.9  2.5%)
had limited effect (Fig. 1 and Supplementary Fig. S1). Since octanoic
acid and decanoic acid are elevated in plasma of patients under-
going the MCT ketogenic diet (Haidukewych et al., 1982; Sills et al.,
1986a, 1986b), our data supports a possible role for decanoic acid
and octanoic acid derivatives in the direct therapeutic mechanism
of the diet in seizure control.
In relation to the MCT ketogenic diet, it must be noted here that
the concentration of decanoic acid in the serum of patients on the
diet (mean concentration 157 mM (Haidukewych et al., 1982)) is
lower than that used in our in vitro assay. Repeating these
epileptiform discharge control experiments using lower decanoic
acid concentration (100 mM), we found a signiﬁcant reduction in
the frequency of epileptiform discharges (Supplementary Fig. S2)
that was superior to equimolar VPA. In addition, decanoic acid
potency was also higher than that of valnoctamide (VCD; see
Supplementary Fig. S1 for structure) e a new second generation
VPA derivative (Bialer and White, 2010). These data indicate that
decanoic acid, at concentrations found in patients during treat-
ment with the ketogenic diet, may provide improved seizure
control compared to current and new-generation treatments.
3.2. The effect of medium chain fatty acids on human histone
deacetylase (HDAC) activity
VPA and related fatty acids have been well documented to
inhibit HDAC activity (Gottlicher et al., 2001; Gurvich et al.,
2004; Phiel et al., 2001), which is likely to cause teratogenicity,
and thus limiting their use during pregnancy (Jentink et al.,
2010; Koren et al., 2006). We thus screened for this important
side effect liability in the compounds showing improved inhi-
bition of epileptiform activity in the PTZ model compared to VPA
(Fig. 2). As expected, VPA showed a dose-dependent inhibition of
HDAC activity, rising to 82.9  1.8% inhibition at 10 mM. Dec-
anoic acid showed no HDAC inhibition at low concentrations, but
a similar inhibitory potency to VPA at 10 mM (79.3  16.5%
inhibition). In contrast, nonanoic acid showed minimal inhibi-
tory activity at all concentrations tested (up to 10 mM). As pre-
dicted in other studies (Eikel et al., 2006), medium chain fatty
acids branched on the second carbon also show high HDAC
inhibitory activity (2-propyloctanoic acid and 2-butyloctanoic
acid); however, compounds with branching on the fourth
carbon did not show HDAC inhibition up to 10 mM. These data
show that decanoic acid and compounds branched on the second
carbon show undesired HDAC inhibition, whilst this is not
evident in related compounds containing a branch on the fourth
carbon.3.3. The effect of medium chain fatty acids on hepatotoxicity in
a human liver cell line (Huh7)
VPAhas also been associatedwith liver toxicity, possibly through
inhibition of b-oxidation (Elphick et al., 2011; Silva et al., 2008). We
therefore monitored the effect of the medium chain fatty acids and
VPA on hepatotoxicity in vitro using human hepatoma cells (Huh7).
A decrease in cell number, relative to control (DMSO), was observed
at the lowest concentration for all compounds, most likely due to an
inhibition of proliferation and not toxicity, consistent with the lack
of effect observed using the lactate dehydrogenase assay at these
concentrations (data not shown). VPA did not demonstrate any
concentration-dependent decrease in viability (Fig. 3), consistent
with the ﬁnding that VPA-mediated liver toxicity is often under-
estimated in vitro (Nassar et al., 2004). Octanoic acid also demon-
strated no signiﬁcant decrease in viability. Both nonanoic acid and
decanoic acid elicited signiﬁcant concentration-dependent toxicity
at concentrations greater than 0.5 mM (IC50 ¼ 2.2 mM and 2.9 mM
respectively). Branched congeners of octanoic acid did not show
effects related to branch position or side chain length, since 4-
methyloctanoic acid and 2-propyloctanoic acid showed only
minimal toxicity (IC50¼ 7.3 mM and 9.0mM respectively), whilst 4-
ethyloctanoic acid and 2-butyloctanoic acidwere signiﬁcantlymore
toxic (IC50 ¼ 2.4 mM and 1.1 mM respectively).
Based upon the balance between seizure control and adverse
effect liability, 4-methyloctanoic and nonanoic acid were selected
for further study.
3.4. Dose dependence of 4-methyloctanoic acid and nonanoic acid
on in vitro epileptiform activity
We then investigated the dose-dependency of 4-methyloctanoic
and nonanoic acid compared to VPA for seizure control in the
in vitro PTZ model (Supplementary Fig. S3). Both novel fatty acids
showed a highly signiﬁcant improvement in seizure control at
1 mM compared to VPA, and showed improved effectiveness at
0.5 mM. These results suggest that lower concentrations of 4-
methyloctanoic acid and nonanoic acid are required to protect
against seizures compared to VPA. Importantly, only minimal
liability for adverse effects was observed at 0.5mM, a concentration
at which signiﬁcant seizure control was achieved (see Figs. 2 and 3).
3.5. The effect of 4-methyloctanoic acid and nonanoic acid on an
in vivo electrical stimulation model of status epilepticus
We next examined the in vivo potency of these compounds,
using an electrical stimulation model of status epilepticus. In these
experiments, perforant path stimulation was used to induce status
epilepticus in awake, freely moving rats (Holtkamp et al., 2001;
Walker et al., 1999). Administration of vehicle control had no effect
on the spike frequency over the 3 h post-stimulation (Fig. 4). VPA
(400 mg/kg) decreased the average spike frequency (64.3  10.5%,
60.6 7.8% and 56.6 6.4% of baseline in the ﬁrst, second and third
hours respectively), but did not stop status epilepticus in any
animal. In contrast, 4-methyloctanoic acid (400 mg/kg) elicited
a much greater decrease (24.9  10.9%, 18.7  13.8% and
28.3  13.0% of baseline in the ﬁrst, second and third hours
respectively), and terminated status epilepticus in all animals.
Nonanoic acid was less effective than 4-methyloctanoic acid, but
more effective than VPA (46.6 8.1%, 18.7  13.8% and 28.3 13.0%
of baseline in the ﬁrst, second and third hours respectively).
Analysis of spike amplitude (Fig. 4A and C) showed a similar
improvement in status control.
Control of behavioural responses associated with seizures
occurrence was also assessed following continuous perforant path
Fig. 2. Structurally-speciﬁc medium chain fatty acids show reduced inhibition of human histone deacetylase enzyme activity. Quantiﬁcation of HDAC inhibition assay employing
human nuclear extracts enzyme (from HeLa cells) as the source of HDAC activity shown as ﬁtted doseeresponse curves for (A) VPA; (B) unbranched medium chain fatty acids (OA,
NA, DA); (C) medium chain fatty acids branched on the second carbon, 2-BO and 2-PO; and (D) medium chain fatty acids branched on the fourth carbon, 4-MO and 4-EO, showing
means  SEM for four independent measurements at each of ﬁve concentrations. (E) Comparison of the HDAC inhibition with different treatments at a concentration of 10 mM,
showing means  SEM for four independent measurements for each compound. ** signiﬁcant difference at p < 0.01 compared to control. þþ signiﬁcant difference at p < 0.01
compared to VPA.
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tonic-clonic seizures (Fig. 4D). By the end of the stimulation, all
animals had reached behavioural seizures characterised as Racine
stage 5. In the vehicle control group, animals gradually recovered
from status epilepticus (illustrated by a reduction in baseline clin-
ical seizure severity immediately after induction to 80.0  8.0%,
60.8  8.1% and 51.8  5.6% of baseline in the ﬁrst 3 h respectively).
VPA resulted in a non-signiﬁcant trend for a reduction in seizure
severity. In contrast, 4-methyloctanoic acid was more potent than
VPA in this model, and led to the complete termination of behav-
ioural seizures in the ﬁrst 2 h (0.0 0.0, 0.0 0.0% and 18.8 11.8%
of baseline in the ﬁrst 3 h respectively). Nonanoic acid did not
terminate behavioural seizures, but showed a highly signiﬁcant
improvement in seizure severity in ﬁrst hour (28.2  10.8%), and
elevated seizure control at later time points compared to
VPA (24.4  12.5% of baseline in both the second and third hours).
There was also a signiﬁcant effect of treatment on normalized
discharge frequency, discharge amplitude and Racine score
(p < 0.0001, p ¼ 0.005, p ¼ 0.001 respectively, repeated measures
ANOVA). Post-hoc analysis revealed that compared to control: VPA,4-methyloctanoic acid and nonanoic all signiﬁcantly reduced spike
frequency (p ¼ 0.01, p < 0.0001, p < 0.001 respectively, Dunnett t
test) and spike amplitude (p< 0.05, p¼ 0.001, p< 0.05 respectively,
Dunnett t test) but only 4-methyloctanoic acid and nonanoic
signiﬁcantly reduced the Racine score (p < 0.05, p < 0.001
respectively). In comparisons between the treatments 4-
methyloctanoic acid had a signiﬁcantly greater effect on spike
frequency and Racine score than did VPA (p < 0.05 for both, Tukey
HSD). In summary, both novel compounds were far more potent at
controlling seizures compared to VPA, with 4-methyloctanoic acid
completely terminating behavioural seizures.
3.6. The effect of 4-methyloctanoic acid and nonanoic acid on
sedation
Neurotoxicological sedation is a typical side effect of most anti-
epileptic drugs, especially at high concentrations. In order to
compare sedation effects caused by 4-methyloctanoic acid and
nonanoic acid to VPA, we ﬁrst administrated 200 mg/kg of VPA and
found no sedation effect (data not shown). Increasing VPA dosage
Fig. 3. Structurally-speciﬁc medium chain fatty acids show variable effects on human liver cell viability. Hepatotoxicity was evaluated by determining the mitochondrial function of
human hepatocyte (Huh7) cells following 24 h treatment, measured by the mitochondrial conversion of MTT into blue formazan that decreases in direct proportion to cell viability.
Data is provided for (A) VPA; (B) unbranched medium chain fatty acids (OA, NA, DA); (C) medium chain fatty acids branched on the second carbon, 2-BO and 2-PO; and (D) medium
chain fatty acids branched on the fourth carbon, 4-MO and 4-EO. Fitted doseeresponse curves (ﬁtting by three parameters, GraphPad) are based on 8 concentrations and with 4
independent measurements of each concentration. (E) Comparison of hepatotoxicity at a concentration of 1 mM, showing means  SEM for four independent measurements for
each compound. * or þ indicate signiﬁcant difference compared to control or VPA respectively, where one, two or three symbols indicate p < 0.5, p < 0.1, or p < 0.01 respectively.
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to nonanoic acid at this dose, whilst 4-methyloctanoic acid elicited
mild sedationegiving amean sedation score of 1.20.2 inﬁrst hour
and no sedation in both the second and third hours. At higher
concentrations (600 mg/kg), VPA elicited a clear range of sedative
effects (mean sedation score 1.1  0.1, 1.0  0.0 and 0.2  0.1 in ﬁrst
3 h respectively),whilst nonanoic acid elicited slight sedation (mean
sedation score of 0.10.1 in ﬁrst hour and no sedation in the second
and third hours; Fig. 5B). Finally, 4-methyloctanoic was more
sedative than VPA at this higher concentration (mean sedation
score: 2.5 0.4, 1.4  0.4 and 1.5  0.7 in ﬁrst 3 h respectively), and
one animal died 170 min after administration of the high dose 4-
methyloctanoic acid. In summary, 4-methlyoctanoic acid elicits
stronger sedative effects whilst nonanoic acid caused a reduced
(minimal) sedative effect compared to VPA.
3.7. The neuroprotective effect of 4-methyloctanoic acid and
nonanoic acid following status epilepticus
Since our data suggest a potential role for medium chain fatty
acids in seizure control, we then extended this study to includepossible neuroprotective effects that may provide an active part in
the protection against epilepsy. Comparison of neuronal loss
following status epilepticus in the absence or presence of treatment
enabled a quantiﬁcation of neuroprotective effects. Following
status epilepticus, the hilus was signiﬁcantly damaged in animals
treated with vehicle control (DMSO; 59.8  9.8% of control,
p¼ 0.008 compared to no status group) (Fig. 6). Neuronal loss in the
hilus was also accompanied by an apparent destruction of CA3 and
CA1 pyramidal layers, while the granule cell layer of the dentate
gyrus and CA2 showed a resistance to neuron loss after status
epilepticus. Application of VPA and 4-methyloctanoic acid were
unable to prevent hilar neuronal loss, 65.0  6.5% of control, and
74.4  8.1% of control, respectively, whilst nonanoic acid provided
protection (98.2  5.9% of control, p ¼ 0.029 and p ¼ 0.045
compared to DMSO and VPA respectively; Fig. 6).
4. Discussion
The (MCT) ketogenic diet is used extensively for treating
refractory childhood epilepsy, although its mechanism of action is
poorly understood. As a potential mechanism for this, the medium
Fig. 4. EEG recording spike frequency and amplitude and seizure behaviour following status epilepticus induction is decreased by 4-methyloctanoic and nonanoic acid compared to
VPA. (A) Illustrative examples of EEG recordings from animals in self-sustaining status epilepticus (SSSE), induced by perforant pathway stimulation, with traces shown prior to
compound administration (baseline) and following administration of control (DMSO), or VPA, 4-MO or NA (all at 400 mg/kg). (B) Time course of the effects on spontaneous spike
frequency following administration of control (DMSO; n ¼ 5), VPA, 4-MO or NA (n ¼ 7 for all at 400 mg/kg) 10 min after stopping perforant path stimulation. (C) Time course of the
effects on spontaneous spike amplitude following administration of control (DMSO; n ¼ 5), VPA, 4-MO or NA (n ¼ 7 for all at 400 mg/kg) 10 min after stopping perforant path
stimulation. (D) Time course of the effects of compounds on behaviour seizure which was scored using the Racine score during SSES induced by perforant pathway stimulation.
P. Chang et al. / Neuropharmacology 69 (2013) 105e114 111chain triglycerides given in the diet are largely composed of two
unbranched fatty acids (octanoic and decanoic acids), and these are
found in elevated levels in the plasma of patients on the diet
(Haidukewych et al., 1982; Sills et al., 1986a, 1986b). We have
previously demonstrated that both compounds related to these
medium chain fatty acids and VPA give rise to similar cellular
effects in a simple biomedical model, Dictyostelium (Chang et al.,
2011; Elphick et al., 2011; Williams et al., 2006, 2002; Xu et al.,
2007). In order to develop these compounds for clinical use in
epilepsy treatment, they must show greater potency than current
anti-epileptic drugs e and preferably in relation to refractory
epilepsy e plus fewer side effects and ideally disease modiﬁcation
(Bialer and White, 2010; Galanopoulou et al., 2012). We chose anFig. 5. Sedation effects for 4-methyloctanoic and nonanoic acid compared to VPA. Time cou
MO or NA at (A) 400 mg/kg or (B) 600 mg/kg. All results are obtained from ﬁve animals. Sed
spontaneous movement; 3, loss of auditory reﬂex; 4, loss of corneal reﬂex; 5, loss of response
Whitney test. *p < 0.05 compared to control; þp < 0.05 compared to VPA; **p < 0.01 comin vitro seizure model that is resistant to a number of antiepileptic
drugs (Armand et al., 1998), to select drugs that are more potent
than VPA, and then tested these in a model of status epilepticus in
which we could test not only an anticonvulsant effect but also
a neuroprotective effect.
We show that the straight chain ten carbon (decanoic), but not
the eight carbon (octanoic) acid, shows strongly improved seizure
control compared to VPA. Our data thus implicates decanoic acid in
the seizure control activity of the MCT ketogenic diet. This role is
further supported since we show signiﬁcant seizure control at
decanoic acid concentrations correlating with levels shown in the
plasma of patients on the diet (Haidukewych et al., 1982). Although
our study shows a lack of effect of octanoic acid in seizure control,rse of the effect on sedative score following administration of control (DMSO), VPA, 4-
ation score: 0, spontaneous movement; 1, intermittent spontaneous movement; 2, no
to tail pinch, with data presented as mean  SEM and signiﬁcance given by the Manne
pared to control; þþp < 0.01 compared to VPA.
Fig. 6. Neuroprotective effects in the hilus of the hippocampus following status epilepticus following nonanoic acid, 4-methyloctanoic acid and VPA treatment. Two months after
induction of status epilepticus (following indicated treatments), hippocampal slices were prepared and neuronal cell loss was visualised (illustrated by diffuse dark staining) in the
hilus (outlined in A). Animals (A) without status epilepticus (control, n ¼ 5) or following status epilepticus that were treated with (B) vehicle only (DMSO) (n ¼ 4); (C) VPA (n ¼ 6);
(D) 4-MO (n ¼ 4); and (E) NA (n ¼ 3) at 400 mg/kg. (F) Quantiﬁcation of neuroprotective effect. Graph shows means  SEM. *p < 0.05 compared to control, **p < 0.01 compared to
control; þp < 0.05 compared to control. Scale bar ¼ 20 mm. DG; dentate gyrus.
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Liu and Pollack, 1994; Loscher and Nau, 1985), a recent study has
shown octanoic acid increases threshold in the PTZ and 6-HZ
seizure test via prior application (Wlaz et al., 2012). Differences
between these outcomes may reﬂect the oral administration of
octanoic acid giving rise to metabolism-derived products blocking
seizure induction (Wlaz et al., 2012) which were not produced in
the other studies (Liu and Pollack, 1994; Loscher and Nau, 1985), or
due to a differential response between pre- and post-seizure
compound treatment.
Although a role for some medium chain fatty acids (Bojic et al.,
1996; Chapman and Meldrum, 1983; Liu and Pollack, 1994; Loscher
and Nau, 1985) and fatty acids branching from the second carbon
(like VPA) have been demonstrated in seizure control (Bialer and
White, 2010; Galanopoulou et al., 2012), this study is the ﬁrst to
identify both nonanoic acid (commonly pelargonic acid) and
medium chain fatty acids branching on the fourth carbon as
effective seizure control treatments. Both these compounds are not
found in MCT oil (Sills et al., 1986a), thus levels of the compounds
have not been investigated in the plasma of patients on the diet.
However, octanoic acids branched at the fourth carbon are found in
lamb fats (Brennand and Lindsay, 1992), at concentrations around
2e5 mg/kg in adipose tissue (Sutherland and Ames, 1994) giving
rise to lamb ﬂavour, and sheep and goat milk fat (but not cow) also
contain small but signiﬁcant amounts of 4-methyloctanoic which
contributes to mutton- and goat-like ﬂavours in both milk and
cheese products (Ha and Lindsay, 1993). Nonanoic acid is also
naturally occurring, both in lamb fat at concentrations up to
250 mg/kg (Sutherland and Ames, 1994), and in various plant
tissues at concentrations up to 20 mg/kg (Berrie et al., 1975). These
concentrations are very low compared to the related octanoic and
decanoic acid found at around 6e7% of coconut fat (Beare-Rogerset al., 2001). These orally ingested medium chain fatty acids
would be expected to be rapidly taken up in the liver (via the portal
vein (St-Onge and Jones, 2002)), and are quickly metabolized via
coenzymeA intermediates through b-oxidation and the citric acid
cycle to produce carbon dioxide, acetate and ketone bodies
(Furman et al., 1965; Huttenlocher et al., 1971; Linscheer et al.,
1966). It remains unclear if either the odd number of carbons in
nonanoic acid, or the branching in 4-methyloctanoic acid elevates
ketone body formation. Our data would suggest, however, that
modifying the medium chain fatty acid content of the MCT diet (for
example to include nonanoic acid or branched chain compounds)
may provide a signiﬁcant improvement to MCT oil in seizure
control.
Continued analysis of 4-methyloctanoic acid and nonanoic acid
demonstrated an improved dose-dependence for seizure control
compared with VPA, and this translated to a greater effect for these
compounds on an in vivo model of status epilepticus. In vitro,
nonanoic acid showed a greater effect than 4-methyloctanoic acid,
but this was reversed in vivo, presumably due to the lower half-life
of straight chain versus branched fatty acids in vivo (Chapman and
Meldrum, 1983) since it would be very rapidly degraded by ﬁrst-
pass metabolism (Furman et al., 1965; Huttenlocher et al., 1971;
Linscheer et al., 1966). The preliminary data presented here suggest
that that 4-methyloctanoic acid and nonanoic acid may be more
potent than VPA in treating seizures.
The mechanism of seizure control exerted by 4-methyloctanoic
acid and nonanoic acid is currently unclear, and speculation on this
mechanism must be based upon the mechanism of both the keto-
genic diet and VPA. The ketogenic diet has a range of potential
therapeutic mechanisms (reviewed in Freeman et al., 2006; Rho
and Sankar, 2008), including the production of ketone bodies
in the liver (acetone, acetoacetic acid, and b-hydroxybutyric acid)
P. Chang et al. / Neuropharmacology 69 (2013) 105e114 113or the regulation of energy metabolism (in the absence of carbo-
hydrates). In our study, where seizure activity was induced in
hippocampal slices in circulating, glucose-rich artiﬁcial cerebro-
spinal ﬂuid, it is unclear if sufﬁcient ketone body formation or
glucose reduction would occur to control seizures in the rapid time
frame shown. Our data instead, suggests a direct mechanism for
seizure control in this model by structurally speciﬁc fatty acids. It
remains to be examined if this mechanism is dependent upon
regulation of phosphoinositide signalling, as initially suggested in
the discovery of these compounds (Chang et al., 2011).
The teratogenicity of VPA is a major limitation in its use, espe-
cially as 25% of people with epilepsy arewomen of childbearing age
(Wallace et al., 1998). VPA teratogenicity has been proposed to
occur through HDAC inhibition (Eikel et al., 2006; Gurvich et al.,
2004; Phiel et al., 2001), as non-teratogenic analogues of VPA do
not inhibit HDACs (Eikel et al., 2006; Phiel et al., 2001). As previ-
ously reported (Eikel et al., 2006), compounds branched on the
second carbon show high HDAC inhibition. Unexpectedly, the
straight chain decanoic acid also showed inhibitory effects at high
concentrations, limiting its potential as a new seizure control
therapy. However, nonanoic acid and compounds branched on the
fourth carbon (4-methyloctanoic and 4-ethyloctanoic acid)
exhibited no effect on HDAC inhibition, suggesting that they are
unlikely to show HDAC inhibition-related teratogenicity. A subse-
quent comprehensive analysis of teratogenicity must include
in vivo studies to examine possible birth defects caused by these
compounds in animal models.
VPA is an idiosyncratic hepatotoxin, most likely due to inhibition
of fatty acid b-oxidation in the mitochondrial matrix (Silva et al.,
2008), increasing the lipid droplet accumulation in hepatocytes
(Elphick et al., 2011; Fujimura et al., 2009). Recent studies have
shown liver cell toxicology (using a Huh7 cell line) caused by
medium chain fatty acids and other VPA-related compounds is
dependent on structure features of the compounds (Elphick et al.,
2011). Thus, in our current study, we examined the hepatotoxic
potential of medium chain fatty acids by determining the mito-
chondrial function of Huh7 cells using the MTT assay. Interestingly,
no common (structurally based) trends were seen for liver cell
toxicology in the tested compounds. From the compounds shown
to inhibit seizure control in vitro above that of VPA, that also lack
HDAC inhibitory effects and show minimal effect on liver cell
survival (with higher IC50 values for hepatotoxicity), 4-
methyloctanoic acid and nonanoic acid provide the best proﬁle.
Sedation is the most common side effect of anti-epileptic
treatments, including VPA, leading to adverse patient response
and often loss of compliance. Our results shows that the sedative
effects of medium chain fatty acids are likely to vary dependant on
structure, since nonanoic acid shows little sedation, whilst 4-
methyloctanoic acid shows relatively strong sedation to that of
VPA with an intermediate effect. Through translational medicinal
chemistry it should be possible to develop a medium chain fatty
acid with increased potency against seizures and low sedative
activity compared to VPA.
Neuronal cell death caused by status epilepticus has been
shown to be a neuropathological feature of temporal lobe epilepsy,
giving rise to enhanced seizure development through hippo-
campal sclerosis and resultant alterations in physiology (Dam,
1980; Scharfman, 2000). Our study conﬁrms neurodegeneration
in the hilus of the dentate gyrus following status epilepticus, as is
evident in patients with temporal lobe epilepsy (de Lanerolle et al.,
1989) and in equivalent animal models (Buckmaster and Jongen-
Relo, 1999). Interestingly, nonanoic acid was more potent than 4-
methyloctanoic acid in preventing hilar neuronal death despite
having a lesser effect on seizure activity, suggesting a disconnec-
tion between these effects. Moreover, these preliminary resultspoint to a potential disease modifying effect of these compounds,
as has been also suggested for the ketogenic diet (Gasior et al.,
2006).
The results of the present study clearly demonstrate the
potential for medium chain fatty acids to provide a highly-
improved clinical proﬁle in the development of more effective
and safer epilepsy treatments than VPA. These compounds include
fatty acids prescribed in the MCT ketogenic diet, shown to be
elevated in patients during treatment (Haidukewych et al., 1982;
Sills et al., 1986a), and provide novel related structures showing
increased potency compared to VPA. We show that a range of
structurally speciﬁc medium chain fatty acids outperform VPA in
seizure control activity, both in vitro and in vivo, whilst having
lower adverse effect proﬁles. Although we show variable sedative
effects, we also show improved neuroprotection (post status). Thus,
the family of medium chain fatty acids identiﬁed here provides an
exciting new ﬁeld of research with the potential of identifying,
stronger, and safer epilepsy treatments.Acknowledgements
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